PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
9.62%
Cash & equivalents growing 9.62% while CRVO's declined -18.27%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
9.62%
Below half of CRVO's -18.27%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.08%
Below half of CRVO's -22.55%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.18%
Both CRVO and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.96%
Higher Long-Term Investments Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.38%
Below half of CRVO's 3498.42%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
8.48%
Below half of CRVO's -19.81%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-5.53%
Less than half of CRVO's 2.61%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6569.50%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
100.00%
Less than half of CRVO's 1191.04%. David Dodd sees fewer expansions in other current obligations.
-5.06%
Less than half of CRVO's 2.52%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2126.46%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.39%
Less than half of CRVO's -27.13%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-1.27%
Less than half of CRVO's 2.52%. David Dodd sees far fewer liability expansions relative to competitor.
3.57%
Less than half of CRVO's 8.74%. David Dodd sees fewer share issuances vs. competitor.
-2.57%
0.5-0.75x CRVO's -4.62%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.56%
Below half CRVO's -27.66%. Michael Burry sees potential underperformance in building shareholder capital.
8.48%
Below half CRVO's -19.81%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.96%
Higher Total Investments Growth compared to CRVO's zero value, indicating better performance.
-6.20%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
-10.07%
Less than half of CRVO's 18.27%. David Dodd sees better deleveraging or stronger cash buildup than competitor.